MeSH term
Frequency | Condition_Probility | Animals | 15 | 0.0 |
Antibodies, Monoclonal/immunology | 4 | 0.0 |
Comparative Study | 12 | 0.0 |
Cross Reactions | 3 | 0.0 |
Female | 19 | 0.0 |
Immunoenzyme Techniques/veterinary | 2 | 20.0 |
Male | 19 | 0.0 |
Research Support, Non-U.S. Gov't | 39 | 0.0 |
Species Specificity | 2 | 0.0 |
Antigens, CD/*analysis | 5 | 0.0 |
Antigens, CD5/analysis | 3 | 6.0 |
B-Lymphocytes/*immunology | 9 | 1.0 |
Humans | 65 | 0.0 |
Immunophenotyping | 18 | 0.0 |
Leukemia, B-Cell, Chronic/*immunology | 3 | 6.0 |
Lymphocyte Activation | 4 | 0.0 |
Reference Values | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 14 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
Antigens, CD20/metabolism | 2 | 9.0 |
B-Lymphocytes/*immunology/metabolism | 2 | 4.0 |
Blotting, Western | 2 | 0.0 |
Flow Cytometry | 19 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Mice | 8 | 0.0 |
Rats | 3 | 0.0 |
Transfection | 3 | 0.0 |
Aged | 14 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Adult | 12 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
Middle Aged | 15 | 0.0 |
Adolescent | 2 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
Signal Transduction | 2 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Antigens, CD/metabolism | 3 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
Immunoglobulins, Light-Chain/metabolism | 2 | 25.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Karyotyping | 3 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 3 | 1.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
Diagnosis, Differential | 8 | 0.0 |
Prognosis | 2 | 0.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Antigens, CD/analysis | 5 | 0.0 |
Immunophenotyping/*methods | 3 | 4.0 |
Sensitivity and Specificity | 2 | 0.0 |
*Immunophenotyping | 3 | 1.0 |
Lymphoma, B-Cell/*immunology | 2 | 5.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Antigens, CD/*immunology | 3 | 0.0 |
Phosphorylation | 4 | 0.0 |
Receptors, Antigen, B-Cell/immunology | 3 | 12.0 |
Conserved Sequence | 3 | 0.0 |
Alleles | 2 | 0.0 |
Antigens, CD/biosynthesis/*genetics/immunology | 2 | 50.0 |
Genes, Immunoglobulin | 2 | 1.0 |
Leukemia, B-Cell, Chronic/*genetics/*immunology | 2 | 40.0 |
Cells, Cultured | 4 | 0.0 |
Flow Cytometry/methods | 3 | 1.0 |
Antigens, CD/*metabolism | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
Leukemia, B-Cell, Chronic/*metabolism | 2 | 16.0 |
Immunoglobulin M/immunology | 2 | 1.0 |
Leukemia, Lymphocytic, Chronic/*genetics/*immunology | 2 | 100.0 |
Signal Transduction/immunology | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
Antigens, CD/*blood | 2 | 1.0 |
Case-Control Studies | 2 | 0.0 |
Alternative Splicing | 3 | 0.0 |
Antigens, CD/*genetics | 5 | 1.0 |
Receptors, Antigen, B-Cell/*genetics | 2 | 18.0 |
Antigens, CD5/*blood | 2 | 33.0 |
*Gene Expression Regulation, Leukemic | 3 | 3.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Base Sequence | 7 | 0.0 |
Immunoglobulin Variable Region/genetics | 2 | 1.0 |
Molecular Sequence Data | 9 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Receptors, Antigen, B-Cell/*physiology | 3 | 3.0 |
Amino Acid Sequence | 6 | 0.0 |
*Lymphocyte Activation | 3 | 0.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Antigens, CD/immunology | 2 | 0.0 |
Cell Line | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Receptors, Antigen, B-Cell/*immunology | 2 | 5.0 |
Antigens, CD/*genetics/metabolism | 2 | 4.0 |
Binding Sites | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
*Cell Adhesion Molecules | 2 | 0.0 |
Flow Cytometry/*methods | 2 | 0.0 |
Immunophenotyping/methods | 2 | 4.0 |
Immunohistochemistry/veterinary | 2 | 15.0 |
In Vitro | 2 | 0.0 |
Immunoglobulins, Heavy-Chain/genetics | 2 | 1.0 |
